3-FA

Bounded publishable correction only: the restricted_other status describes verified state-law controls in Illinois and Nevada (with Florida reported as a cautious corroborative broad Fluoroamphetamine listing), not a nationwide federal classification. Illinois expressly places 3-fluoroamphetamine in Schedule I, and Nevada's regulation expressly includes 3-fluoroamphetamine and 3-FA; Florida's statute lists Fluoroamphetamine but does not specify the positional isomer, so no definitive Florida 3-FA conclusion is asserted. Current federal primary materials support only a bounded absence from the DEA reference list plus conditional analogue exposure under 21 U.S.C. §§ 802(32) and 813. They do not establish that 3-FA is definitively federally unscheduled or definitively a federal Schedule I analogue. The old nationwide 'Unscheduled (analogue liability)' row is therefore corrected to a restricted_other label whose scope is expressly limited to these verified state-law controls and whose caveat preserves the unresolved federal and broader state questions.

The legacy assertion that 3-FA is listed in Finland's Government decree is supported. The status label 'Scheduled narcotic' is normalized to the required canonicalStatus 'prohibited': 3-FA is expressly named in current Annex IV of Decree 543/2008 as amended by 651/2026, and Narcotics Act Section 5 prohibits ordinary possession, use, handling, trade, distribution, transport, import/export, manufacture and production of narcotic drugs. The Act preserves narrowly defined medicinal, research and control-purpose exceptions; no general consumer or recreational exception was identified. This is a nationwide Finnish classification; no subnational exception was inferred.

The legacy Schedule 3 (Class C) conclusion is supported for the live article's stated identity, 1-(3-fluorophenyl)propan-2-amine (3-fluoroamphetamine), but the wording should be corrected for precision. 3-FA is not shown as an individually named entry in the current Medsafe medicine-classification search; the publishable basis is the Misuse of Drugs Act 1975 Schedule 3 Part 7 generic amphetamine-analogue provision applied to the molecule's alpha-methylphenethylamine nucleus and fluoro phenyl substitution. Treat the result as a Class C controlled-drug classification for ordinary non-exempt handling, not as a claim that the trivial name is separately printed in the schedule. Customs and Medsafe guidance confirm that import, supply and administration require the applicable licence, approval or statutory exemption; no unrestricted consumer or recreational exception was identified. This is a nationwide New Zealand classification; no subnational exception was inferred.

Corrected rather than simply retaining the legacy wording. The exact 3-FA identity is verified by UNODC, and the 2015/7238 Turkish Annex structurally captures it as an alpha-methyl, meta-fluoro derivative of the defined 2-phenylethylamine scaffold. The decision places covered compounds under Law No. 2313, while Turkey's official National Police report describes the 2015 Generic Classification System as covering most NPS before entry into the country. The ordinary result is prohibited/controlled handling: TCK 188 covers unlicensed manufacture, import/export and trafficking-related domestic handling, while TCK 191 addresses personal-use purchase, possession and use. The former notes' unqualified statement that every form of possession is prohibited is narrowed because the criminal provisions distinguish trafficking-related possession from personal-use conduct and preserve licensing/statutory rules. Law No. 7445's 2023 amendment adds amphetamine derivatives to the TCK 188(4)(a) aggravation list but is not treated as the source of the underlying schedule classification. No general recreational or consumer exception was identified; any medicinal, scientific, licensing or case-specific defenses require separate verification.

The legacy row's generic status 'Controlled substance' and October 2015 date are historically supported, but the current legal characterization is more precise: 3-FA (CAS 1626-71-7) is entry 15 of China's non-medical narcotic and psychotropic catalogue and is subject to the current regulation's prohibition on production, operation, use, storage and transport, with only regulated experimental research permitted. The 2025 consolidated catalogue repealed the former 2015 supplemental catalogue, and the 2026-07-01 amendment adds other substances; the current 2026-updated official police directory still displays 3-FA entry 15. This is a nationwide China classification; no subnational exception was inferred.

The legacy NpSG classification is substantially supported but corrected for precision. Under the current generic Anlage 1 Nr. 1 structure, 3-FA means 1-(3-fluorophenyl)propan-2-amine and is covered as a new psychoactive substance unless the particular substance is independently a BtMG narcotic. Section 3 prohibits possession and the other listed handling, but § 4's criminal provisions are narrower: manufacture and movement into Germany are criminalized there when done for placing into commerce, while trade, placing into commerce and administration are independently listed; simple possession is not itself listed in § 4. The canonical controlled-but-not-ordinary-consumer-legal mapping is restricted_other, not unscheduled and not prohibited in the sense of a BtMG possession crime. The official BtMG Annex I–III tables were inspected for identity overlap; the observed 4-FA and 3-FMA rows are distinct compounds. This conclusion is limited to the stated 3-FA identity and ordinary non-exempt handling.

The legacy wording is corrected to the canonical restricted_other status and the official lower-case category name Verzeichnis e. The current authoritative Fedlex consolidation expressly names 3-FA and supplies the same 1-(3-Fluorphenyl)propan-2-amin identity as the live 3-FA article. BetmVV-EDI Article 1(2)(a) treats substances listed in Annexes 1–6 as controlled substances and Article 2(2) places Verzeichnis e in Annex 6. BetmKV Article 3(2)(e) subjects Verzeichnis-e entries to the control measures applicable to Verzeichnis-a narcotics, Article 5(2) assigns operating permits for handling Verzeichnis-e substances to the EDI, and Article 11(1) requires an operating permit for listed handling activities including manufacture, obtaining, brokering, import/export, supply and trade. BetmG Article 7(1) requires EDI authorization and compliance with its conditions for cultivating, manufacturing, importing, exporting, storing, using or placing Article 7 materials/products into circulation; Article 20(1)(c) provides up to three years' imprisonment or a monetary penalty for specified unauthorized conduct involving Article 7 substances and products. The exact item-13 text supplies no separate consumer or industrial exception, so none is asserted. This is a permit-based restricted_other classification, not an assertion that 3-FA is in Verzeichnis d or that every possible act is categorically prohibited.

The legacy Class A conclusion is supported for the live row's stated identity, 1-(3-fluorophenyl)propan-2-amine (3-fluoroamphetamine). The precise legal basis is the current generic ring-substituted phenethylamine clause in Schedule 2 Part I paragraph 1(c), rather than a separately named 3-FA entry or an undefined analogue principle. The matching Schedule 1 paragraph 1(d) in the Misuse of Drugs Regulations 2001 confirms the regulatory schedule. Sections 3, 4 and 5 make the ordinary import/export, production, supply and possession restrictions applicable subject to the Act's regulations, licences and statutory exceptions; Schedule 4 confirms the severe Class A maximum punishments. The result is limited to the stated molecular identity and ordinary non-exempt handling.